SV1999000026A - Combinaciones de estatina-inhibidor de mmp - Google Patents

Combinaciones de estatina-inhibidor de mmp

Info

Publication number
SV1999000026A
SV1999000026A SV1999000026A SV1999000026A SV1999000026A SV 1999000026 A SV1999000026 A SV 1999000026A SV 1999000026 A SV1999000026 A SV 1999000026A SV 1999000026 A SV1999000026 A SV 1999000026A SV 1999000026 A SV1999000026 A SV 1999000026A
Authority
SV
El Salvador
Prior art keywords
statin
mmp inhibitor
inhibitor combinations
combinations
mmp
Prior art date
Application number
SV1999000026A
Other languages
English (en)
Spanish (es)
Inventor
Newton Roger Schofield
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SV1999000026A publication Critical patent/SV1999000026A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SV1999000026A 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp SV1999000026A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
SV1999000026A true SV1999000026A (es) 2000-01-18

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1999000026A SV1999000026A (es) 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp

Country Status (18)

Country Link
EP (1) EP1063991A1 (cg-RX-API-DMAC7.html)
JP (1) JP2002506818A (cg-RX-API-DMAC7.html)
KR (1) KR20010041916A (cg-RX-API-DMAC7.html)
AR (1) AR018113A1 (cg-RX-API-DMAC7.html)
AU (1) AU1591699A (cg-RX-API-DMAC7.html)
BR (1) BR9815745A (cg-RX-API-DMAC7.html)
CA (1) CA2309588A1 (cg-RX-API-DMAC7.html)
CO (1) CO5070670A1 (cg-RX-API-DMAC7.html)
GT (1) GT199900039A (cg-RX-API-DMAC7.html)
HN (1) HN1999000029A (cg-RX-API-DMAC7.html)
MY (1) MY140504A (cg-RX-API-DMAC7.html)
NZ (1) NZ505994A (cg-RX-API-DMAC7.html)
PA (1) PA8469001A1 (cg-RX-API-DMAC7.html)
PE (1) PE20000348A1 (cg-RX-API-DMAC7.html)
SV (1) SV1999000026A (cg-RX-API-DMAC7.html)
UY (1) UY25436A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999047138A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA992106B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US7816347B2 (en) 2004-12-15 2010-10-19 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ127198A3 (cs) * 1995-11-02 1998-12-16 Warner-Lambert Company Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob
CZ294063B6 (cs) * 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
MXPA99001974A (es) * 1996-12-09 2002-03-27 Warner Lambert Co Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
KR20010041916A (ko) 2001-05-25
BR9815745A (pt) 2000-11-14
WO1999047138A1 (en) 1999-09-23
UY25436A1 (es) 2001-10-25
JP2002506818A (ja) 2002-03-05
PE20000348A1 (es) 2000-05-22
AR018113A1 (es) 2001-10-31
AU1591699A (en) 1999-10-11
ZA992106B (en) 1999-09-30
NZ505994A (en) 2003-10-31
CO5070670A1 (es) 2001-08-28
GT199900039A (es) 2000-09-06
CA2309588A1 (en) 1999-09-23
HN1999000029A (es) 1999-09-29
MY140504A (en) 2009-12-31
EP1063991A1 (en) 2001-01-03
PA8469001A1 (es) 2002-09-17

Similar Documents

Publication Publication Date Title
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
BR0113669A (pt) Inibidores da desacetilase
BR0113661A (pt) Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2
EA199900373A2 (ru) Фармацевтические композиции
ES2148345T3 (es) Composicion farmaceutica con ciclosporina a, un derivado de vitamina e y un emulsionante.
BR0317715A (pt) Composições e processos de uso de collajolie
HN2001000146A (es) Derivados de pirazol
HN1997000099A (es) Inhibidores de metaloproteasas matriciales basados en
ES2178298T3 (es) Compuestos anti-inflamatorios.
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
DE69810328D1 (de) Zusammenstellung aus gemischten cyanoacrylatestern
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
ES2164182T3 (es) Benzociclopentanoxazolidinonas que contienen heteroatomos con actividad antibacteriana.
DK1393741T3 (da) Lagerstabil, flydende fibrinogen-formulering
PT1105122E (pt) Composicoes farmaceuticas que contem inibidores de lipase
UY25714A1 (es) Método para tratar ateroesclerosis empleando un inhibidor de ap2 y combinación.
ES2182874T3 (es) Procedimiento de tratamiento de las uñas.
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
BR9815469A (pt) Inibidores de protease
AU2003296807A1 (en) Cosmetic composition comprising a metalloproteinase inhibitor and a lipopeptide
ES2184340T3 (es) Combinaciones de inhibidores de la enzima de conversion de la angiotensina e inhibidores de la enzima metaloproteinasa matricial.
BR9910539A (pt) Derivados de 2 - (2 - clorofenil) - 3,4 - dihidro - 2h - pirrol
DK1105114T3 (da) Nimesulidholdige topiske farmaceutiske sammensætninger
ES2176714T3 (es) Preparaciones desodorantes.
DE60114043D1 (de) Zahnputzzusammensetzung

Legal Events

Date Code Title Description
FG Grant
FD Lapse